logo
Plus   Neg
Share
Email

Idera Pharma Announces Results From Phase 2 Clinical Trial Of IMO-2055

Idera Pharmaceuticals Inc. (IDRA) announced results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company's investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux (cetuximab) for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck or SCCHN in patients who previously progressed on chemotherapy.

The company noted that the study did not meet its primary endpoint of improved progression-free survival following treatment with IMO-2055 in combination with cetuximab compared to treatment with cetuximab alone. The median progression-free survival based on investigator assessments was 2.9 months in both arms; based on independent radiology review, it was 1.9 months in the cetuximab arm and 1.5 months in the combination arm.

The Phase 2 trial was designed and conducted by Merck KGaA of Darmstadt, Germany, under Idera's oncology collaboration with Merck KGaA that was terminated in November 2011.

As part of the termination, Idera regained from Merck KGaA all rights for developing TLR9 agonists for the treatment of cancer, including all rights to IMO-2055, and Merck KGaA agreed to conduct the Phase 2 trial through completion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition. Walt Disney Co.'s (DIS) streaming service Disney+ will be launched on March 24 in the UK and other markets in the Western Europe, one week earlier than originally planned on March 31. Pricing also been confirmed at 5.99 pounds/6.99 euros per month or 59.99 pounds/69.99 euros for an annual subscription....
Follow RTT
>